Literature DB >> 15959841

Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.

P Roggenkämper1, W H Jost, K Bihari, G Comes, S Grafe.   

Abstract

NT 201 is a new development of Botulinum Toxin Type A free of complexing proteins. In this double-blind Phase III trial, we compared the efficacy and safety of NT 201 and BOTOX in patients suffering from blepharospasm. Of 304 enrolled patients, 300 patients received study medication (intent-to-treat population), and 256 patients completed the study as planned (per-protocol population). At baseline, patients received a single injection of NT 201 or BOTOX (<or=35 units per eye). No significant differences were found between NT 201 and BOTOX for all efficacy and safety variables three weeks after injection. Both the NT 201 and the BOTOX group showed a decrease in the Jankovic Rating Scale (JRS) sum score signifying an improvement in the symptoms of blepharospasm during this time period. These data show that NT 201* is an effective and safe treatment for patients suffering from blepharospasm.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15959841     DOI： 10.1007/s00702-005-0323-3

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  27 in total

1.  Botulinum toxin type A purified neurotoxin complex for the treatment of blepharospasm: a dose-response study measuring eyelid force.

Authors:  H Iwashige; Y Nemeto; H Takahashi; T Maruo
Journal:  Jpn J Ophthalmol       Date:  1995       Impact factor: 2.447

2.  Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.

Authors:  H Göschel; K Wohlfarth; J Frevert; R Dengler; H Bigalke
Journal:  Exp Neurol       Date:  1997-09       Impact factor: 5.330

3.  Basal ganglia and thalamo-cortical hypermetabolism in patients with spasmodic torticollis.

Authors:  G Galardi; D Perani; F Grassi; S Bressi; S Amadio; M Antoni; G C Comi; N Canal; F Fazio
Journal:  Acta Neurol Scand       Date:  1996-09       Impact factor: 3.209

4.  Development of resistance to botulinum toxin type A in patients with torticollis.

Authors:  P Greene; S Fahn; B Diamond
Journal:  Mov Disord       Date:  1994-03       Impact factor: 10.338

5.  Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors: 
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

Review 6.  Pathophysiology of dystonia: a neuronal model.

Authors:  Jerrold L Vitek
Journal:  Mov Disord       Date:  2002       Impact factor: 10.338

7.  Botulinum A toxin injection as a treatment for blepharospasm.

Authors:  A B Scott; R A Kennedy; H A Stubbs
Journal:  Arch Ophthalmol       Date:  1985-03

8.  Blepharospasm: demographic and clinical survey of 250 patients.

Authors:  J Jankovic; J Orman
Journal:  Ann Ophthalmol       Date:  1984-04

9.  Abnormal eye movements in blepharospasm and involuntary levator palpebrae inhibition. Clinical and pathophysiological considerations.

Authors:  M Aramideh; L J Bour; J H Koelman; J D Speelman; B W Ongerboer de Visser
Journal:  Brain       Date:  1994-12       Impact factor: 13.501

10.  Blepharospasm: a review of 264 patients.

Authors:  F Grandas; J Elston; N Quinn; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154
View more
  71 in total

1.  Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay.

Authors:  Dirk Dressler; Gerd Mander; Klaus Fink
Journal:  J Neural Transm (Vienna)       Date:  2011-10-05       Impact factor: 3.575

Review 2.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

3.  [Pharmacology of botulinum toxin drugs].

Authors:  D Dressler
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

4.  American academy of physical medicine and rehabilitation, 71st annual assembly.

Authors:  Walter Alexander
Journal:  P T       Date:  2010-12

Review 5.  Botulinum neurotoxin - from laboratory to bedside.

Authors:  K A Foster; H Bigalke; K R Aoki
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 6.  From poison to remedy: the chequered history of botulinum toxin.

Authors:  F J Erbguth
Journal:  J Neural Transm (Vienna)       Date:  2007-04-26       Impact factor: 3.575

Review 7.  Dystonia rating scales: critique and recommendations.

Authors:  Alberto Albanese; Francesca Del Sorbo; Cynthia Comella; H A Jinnah; Jonathan W Mink; Bart Post; Marie Vidailhet; Jens Volkmann; Thomas T Warner; Albert F G Leentjens; Pablo Martinez-Martin; Glenn T Stebbins; Christopher G Goetz; Anette Schrag
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

8.  Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D M Simpson; A Blitzer; A Brashear; C Comella; R Dubinsky; M Hallett; J Jankovic; B Karp; C L Ludlow; J M Miyasaki; M Naumann; Y So
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

9.  [Does dilution have an impact on cosmetic results with BoNT/A? Complex-protein-free BoNT/A for treatment of glabella lines].

Authors:  W Prager; I Zschocke; C Reich; L Brocatti; K Henning; V Steinkraus
Journal:  Hautarzt       Date:  2009-10       Impact factor: 0.751

10.  Newly Designed Quinolinol Inhibitors Mitigate the Effects of Botulinum Neurotoxin A in Enzymatic, Cell-Based, and ex Vivo Assays.

Authors:  Paul T Bremer; Michael Adler; Cecilia H Phung; Ajay K Singh; Kim D Janda
Journal:  J Med Chem       Date:  2017-01-03       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.